2024 Trends, Events, and Developments (TEDs) in the Payer World – Hot Summer 2024 Topics  

Welcome to the 2024 TEDs issue on Hot Summer 2024 Topics! I am Cynthia Miller, MD, MPH, FACP, Vice President Medical Director—Access Experience Team, editor of All Access Newsletter. This edition will focus on topics that are hot this summer in the payer space, including digital health, rare disease, and specialty pharmacy. Our expert ex-payers will provide insights into these trends and developments and how they foresee them impacting the healthcare system, especially patients, health systems, and the pharmaceutical industry.

Digital Tools in Clinical Trials and Real-World Evidence, Barbara Henry, Senior Director, Access Experience Team—Access Experience Team

Barbara discusses how data from wearable health devices can be used in clinical trials, real-world studies, population health research, and innovation. She gives case examples of how wearables may be used and the barriers that need to be overcome for their successful implementation in clinical trials.

The Role of Digital Health in Cardiovascular-Kidney-Metabolic Syndrome, Cynthia Miller, VP, Medical Director, Access Experience Team—Access Experience Team

In my article, I examine the current role of digital health in cardiovascular-kidney-metabolic (CKM) syndrome and the barriers to adoption, from investment to reimbursement. I propose several key considerations for evaluating digital health in CKM syndrome.

The Role of Contracting in Rare Disease, Amy Martin, VP, Access Experience Team—Access Experience Team

Next, Amy defines the issues around negotiation for access in rare disease. She draws on her experience in contracting to evaluate the opportunities in the rare disease space to maximize access for medications on either the medical or the pharmacy benefit.

Health Systems’ Specialty Pharmacies and Their Advantage, Kris Kang, VP, Access Experience Team—Access Experience Team

Finally, Kris considers the motivators behind health systems that have in-house specialty pharmacies (SPs). She offers several reasons why manufacturers may want to leverage in-house SPs to improve product access and increase demand.

We believe you will find this issue on the hot summer 2024 topics and the impact on market access insightful as you navigate the payer landscape. As always, please feel free to drop me a note and let me know if you have a topic suggestion for the payer team to address, and we’ll do our best to cover it in a future edition.

Best Regards,

Cynthia Miller, MD, MPH, FACP
VP, Director, Access Experience Team
EMAIL CYNTHIA